Drugs / Prizloncabtagene Autoleucel
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04696432 | Nov 2020 → Jul 2023 | B-cell non-Hodgkin lymphoma | Tianjin Medical University Cancer Institute and Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04655677 | Oct 2020 → Feb 2024 | B-cell non-Hodgkin lymphoma | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04693676 | Aug 2020 → Dec 2023 | B-cell non-Hodgkin lymphoma | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT04317885 | Nov 2019 → Jun 2023 | B-cell non-Hodgkin lymphoma | Shanghai Tongji Hospital, Tongji University School of Medicine | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05800977 | Feb 2023 → Mar 2027 expected | aggressive B-cell non-Hodgkin lymphoma | Shanghai AbelZeta Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05421663 | Aug 2022 → Dec 2028 expected | diffuse large B-cell lymphoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-16 | Shanghai AbelZeta Ltd. | AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma abelzeta.com ↗ |
| 2025-06-16 | Shanghai AbelZeta Ltd. | AbelZeta Announces Promising Long-Term Outcomes for C-CAR039, a Novel CD19/CD20 Bi-Specific CAR-T Therapy, in Patients with R/R B NHL at EHA 2025 abelzeta.com ↗ |
| 2025-06-13 | Janssen Research & Development, LLC | Johnson & Johnson’s dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma jnj.com ↗ |
| 2025-06-13 | Janssen Research & Development, LLC | Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma jnj.com ↗ |
| 2023-12-12 | Shanghai AbelZeta Ltd. | AbelZeta Presents Data from Two Clinical Studies Relating to its Immuno-Oncology Drug Development at the 65th ASH Annual Meeting abelzeta.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prizloncabtagene Autoleucel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04655677 ↗ |
| Known as | Prizlo-Cel | “Prizloncabtagene autoleucel (Prizlo-Cel)” NCT05421663 ↗ |
| Known as | prizlon-cel | “evaluate safety of Prizloncabtagene Autoleucel (Prizlon-cel) and establish the recommended Phase 2 dose (RP2D)” NCT05800977 ↗1“Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric antigen receptor T cell” PMID 39813680 ↗ Apr 2025 |
| Known as | Prizloncabtagen autoleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314764 ↗ |
| Action | Deplete | “targets and eliminates CD19/CD20-positive tumor cells” PMID 39813680 ↗ Apr 2025 |
| Modality | Cell therapy | “a novel bispecific chimeric antigen receptor T cell” PMID 39813680 ↗ Apr 2025 |
| Route | Intravenous | “single infusion intravenously” NCT04317885 ↗ |
| Target | CD19 | “Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric antigen receptor T cell, targets and eliminates CD19/CD20-positive tumor cells.” PMID 39813680 ↗ Apr 2025 |